29th July, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Press Release and Investor Presentation – Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026

Dear Sir / Madam,

Further to our intimation made earlier with regard to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026 ('Financial Results'), please find enclosed herewith the Press Release and the Investor Presentation on the Financial Results.

The above information is also available on the website of the Company at www.piramalpharma.com.

You are requested to kindly take the above information on record.

Yours truly,
For **Piramal Pharma Limited**

Maneesh Sharma
Digitally signed by Maneesh Sharma
Date: 2026.07.29 20:37:46 +05'30'

Maneesh Sharma
Company Secretary & Compliance Officer
Encl.: a/a

PRESS RELEASE

Piramal Pharma Limited Announces Results for Q1 FY27

Mumbai, India | July 29, 2026: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026.

Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars	*Q1FY27*	*Q1FY26*	*% Change*
Revenue from Operations	**2,270**	**1,934**	**17%**
CDMO	1,187	997	19%
CHG	743	637	17%
PCH	347	302	15%
EBITDA	**285**	**165**	**72%**
EBITDA Margin	**12.5%**	**8.5%**	
PAT (before exceptional item)	**(69)**	**(102)**	***32%***
Exceptional Item	-	21	NM
PAT (after exceptional item)	**(69)**	**(82)**	***15%***

Note: Exceptional items in Q1FY26 include one-time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023

Key Highlights

- **Revenue**: Healthy 17% revenue growth, supported by strong performance across all three businesses.
- **EBITDA Margin**: EBITDA increased by 72%, with EBITDA margin expanding by approximately 400 basis points to 12.5%, reflecting improved operating leverage and execution.
- **Improved Operating Performance:** Higher capacity utilization, operating leverage, pricing discipline and operational excellence supported EBITDA margin expansion.
- **Best-in-Class Quality**: Sellersville facility in the US received an Establishment Inspection Report from the US FDA, successfully concluding the inspection. Maintain our Zero OAI status till date.

Nandini Piramal, Chairperson, Piramal Pharma Limited said, *"We have started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion. Our CDMO business delivered broad-based growth across India and overseas sites, supported by an enhanced commercial team, healthy RFP activity and order inflows, and strong execution. In Complex Hospital Generics, we maintained leadership in key therapies, gained traction in ex-US inhalation anesthesia markets, and continued progression on integration of Kenalog®. Our Consumer Healthcare business delivered yet another quarter of robust growth, driven by Power Brands, e-commerce, wider distribution, premiumization, and disciplined brand investments.*

Encouraged by this momentum, we look forward to delivering sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment."

Key Business Highlights

Contract Development and Manufacturing Organization (CDMO):

- **Broad-based growth** across India and overseas sites, supported by healthy order inflows and strong execution across the network.
- **Strengthened commercial capabilities** through an expanded commercial team, sharper market coverage and deeper customer engagement.
- **Improved Biopharma funding** supported increase in RFPs, though customer decision-making timelines remains prolonged. Maintaining our win rates and conversion of these RFPs into orders will be the key driver of growth.
- **Improved Execution and Operating Leverage:** Higher utilization, pricing discipline and operational excellence drove EBITDA margin expansion across most sites despite inflationary pressures.
- **Building upon our ADC Capabilities:** Inaugurated the commercial-scale payload-linker suite at Riverview (US), while the Lexington (US) sterile injectable capacity expansion remains on track.
- **Strategic Partnerships:** Collaborated with Ajinomoto Bio-Pharma Services for next-gen conjugation technology.
- **Quality:** Sellersville facility received an EIR from the US FDA. The business continues to maintain its Zero OAI track record to date.

Complex Hospital Generics (CHG):

- **Inhalation Anesthesia:** Retained leadership in the US Sevoflurane market with a 48% value share and witnessed encouraging traction across select ex-US markets. *(Source: IQVIA)*
- **Kenalog®:** Progressing on integration activities. Expect supplies to start from Q2FY27.
- **Intrathecal Therapy:** Maintained our #1 position in the US intrathecal Baclofen market. *(Source: IQVIA)*
- **Injectable Pain Management:** Collaborating with suppliers to enhance product availability.
- **Differentiated and Specialty Products:** Continued investments in 505(b)(2) products, complex and differentiated generics, branded products, through in-licensing and co-development.

Piramal Consumer Healthcare (PCH):

- **Power Brands:** Grew 23% year-on-year and contributed 53% of Consumer Healthcare sales.
- **E-commerce:** Grew 40% year-on-year and contributed 28% of sales.
- **i-choose:** Launched a new master brand bringing together the women's intimate care portfolio under a unified identity.
- **Brand Investments:** Invested approximately 12% of sales in media and trade promotion across digital and traditional channels.
- **Profitable Growth:** Premiumization, judicious pricing and cost-optimization initiatives helped mitigate raw-material inflation and supported EBITDA performance.

Consolidated Profit and Loss Statement

(in ₹ Crores or as stated)

Particulars	Quarterly		
	Q1FY27	Q1FY26	YoY %
Revenue from Operations	**2,270**	**1,934**	**17%**
Other Income	89	58	53%
Total Income	**2,359**	**1,992**	**18%**
Material Cost	852	694	23%
Employee Expenses	676	619	9%
Other Expenses	547	514	6%
EBITDA	**285**	**165**	**72%**
Interest Expenses	88	86	2%
Depreciation	224	197	13%
Share of Net Profit of Associates	20	19	5%
Profit Before Tax	**(7)**	**(100)**	**93%**
Tax	62	3	2,211%
Net Profit after Tax	**(69)**	**(102)**	**32%**
Exceptional item[1]	-	21	NM
Net Profit after Tax after Exceptional Item	**(69)**	**(82)**	**15%**

Note: Exceptional items in Q1FY26 include one-time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023

Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **30th July 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q1 FY2027 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 30th July 2026	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 12:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 05:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call –Click here	

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17[1] global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

1. Includes one facility via PPL's minority investment in Yapan Bio.

For Investor Queries:

Gagan Borana
Investor Relations & Enterprise Risk Management
gagan.borana@piramal.com

Madhusudan Dalmia
Investor Relations
madhusudan.dalmia@piramal.com

For Media Queries:

Madiha Vahid
Lead – Branding & Communications
madiha.vahid@piramal.com

Piramal
Pharma Limited

Q1FY27 Results

July 2026

Disclaimer

Piramal Pharma Limited

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Piramal Pharma Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever.

Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'.

Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to Company's ability to successfully implement its strategy, the Company's growth and expansion plans, the performance of the Indian economy and of the economies of various international markets, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, income or cash flow projections, the performance of the industry in India and world-wide, exposure to market risks as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially from results expressed in or implied by this Presentation.

The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Given these uncertainties and other factors, viewers of this Presentation are cautioned not to place undue reliance on these forward-looking statements. The information in this Presentation does not constitute financial advice (nor investment, tax, accounting or legal advice) and does not take into account an investor's individual investment objectives, including the merits and risks involved in an investment in the Company or its securities, or an investor's financial situation, tax position or particular needs. Past performance information in this Presentation should not be relied upon as an indication of (and is not an indicator of) future performance.

This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Companies Act, 2013, together with the rules and regulations made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation, and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. The Presentation has not been independently verified and any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

The contents of this Presentation are strictly confidential and may not be copied or disseminated, reproduced, re-circulated, published, advertised or redistributed, in whole or in part, to any other person or in any media, website or otherwise in any manner without the Company's written consent.

Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period. For the ease of presentation, certain financial information herein has been rounded off to one decimal place or two decimal places or whole numbers, as the case may be.

Performance Highlights

Piramal
Pharma Limited

A Positive Start to FY2027: Momentum Across All Three Businesses

Piramal Pharma Limited

Nandini Piramal

CHAIRPERSON

"We have started FY2027 on a strong note. As guided, all the three businesses delivered healthy revenue growth with improvement in EBITDA margins.

01 CDMO **Broad-based performance across India and overseas sites; Focus on strong execution**

Favorable industry trends, diversified customer demand, enhanced commercial team and strong execution across the network position us well for sustained growth and margin improvement.

02 CHG **Pick-up in ex-US inhalation anesthesia sales; Kenalog supplies to start from Q2FY27**

Delivered a resilient Q1, sustaining leadership in core therapies, expanding ex-US traction, progressing Kenalog integration and differentiated pipeline initiatives, while maintaining cost discipline amid supply and input-cost headwinds.

03 PCH **Power brands and e-commerce continue to outperform**

Delivered strong mid-teen growth, driven by Power Brands, e-commerce expansion and disciplined brand investments. Supported by premiumization, wider distribution and profitability initiatives, the business remains well positioned for sustainable, profitable growth.

We expect to build on this strong start through the remainder of FY27, delivering robust revenue growth and significant expansion in profitability.

Q1FY27 Financial Performance: Broad-Based Growth & Margin Expansion

Piramal Pharma Limited

Revenue from Operations

(In ₹ Crore)

17 %



EBITDA

(In ₹ Crore)

72 %



EBITDA Margin

400 bps



CDMO

(In ₹ Crore)

19 %



CHG

(In ₹ Crore)

17 %



PCH

(In ₹ Crore)

15 %



CDMO Business: Return to Growth

Key Highlights

Strong start to the year with 19% YoY revenue growth driven by:

- **Healthy pick-up in RFPs and order inflows across multiple sites supported by enhanced commercial team and improved win rates**
  - **Significant surge in RFP activity in the last few quarters**, however, customer decision-making timelines remains prolonged. Maintaining our win rates and conversion of these RFPs into orders will be the key driver of growth.
  - Healthy demand for **differentiated capabilities** and **innovation related work.**
- **Favorable external factors – Biopharma funding and supply-chain diversification**
  - **Biopharma funding** in H1CY26 up over 100% vs H1CY25. (Industry reports)
  - Geopolitical & trade uncertainties are accelerating **supply-chain diversification**, driving demand for **reliable multi-site CDMO partners**.
- **Superior execution with improved profitability across India and overseas sites**
  - **Margin expansion across most sites** driven by improved utilization, pricing discipline and operational excellence, despite inflationary pressures.
  - **Enhanced customer satisfaction scores** underscore strong operational execution.
  - **Maintained best-in-class quality track record** with Zero OAI till date.

Revenue Performance

(In ₹ Crore)



Advancing our ADC Platform: Capacity, Capability & Partnerships

Piramal
Pharma Limited

Building on our integrated ADCelerate™ platform — 20+ years in ADCs

ON TRACK

Lexington, US

Scaling sterile injectables capacity

- **Key additions -** Filling line, commercial lyophilizers, capping machine, external vial washer
- Strengthens **sterile fill-finish** — the final step of the integrated ADC platform
- Part of the **US$90M expansion**; seeing strong customer interest

COMPLETED

Riverview, US

Commercial manufacturing capability

- **Commercial-scale** payload-linker development & manufacturing
- **Advanced containment, automation & analytics** for seamless scale-up
- Dedicated payload-linker supply feeding **ADCelerate™**

PARTNERSHIP

Ajinomoto Bio-Pharma

Access to next-gen conjugation technology

- **Site-specific conjugation** for homogeneous, higher-quality ADCs
- **Works on native antibodies** — no antibody re-engineering
- **Two-way referral + technology transfer** (Master Technology Agreement)

Piramal
Pharma Limited

AJINOMOTO
BIO•PHARMA
SERVICES

Complex Hospital Generics Business: Building Traction

Piramal Pharma Limited

Key Highlights

❖ **Inhalation Anesthesia – Sustaining US Leadership; Building Ex-US Traction**

- **US –** Maintained leadership in Sevoflurane, **#1 Rank with 48% value share**.
- **Ex-US Markets** – Healthy pickup across select markets, supported by strong ROW Sevoflurane performance.

❖ **Intrathecal Therapy – Continued US Market Leadership**

- **Maintained #1 Rank** in intrathecal Baclofen in the US, reinforcing our strength in differentiated hospital therapies.

❖ **Injectable Pain Management – Focused Actions to Improve Supply**

- **Collaborating with suppliers** to enhance product availability.

❖ **Kenalog Integration – Supplies to Start from Q2FY27**

- Progressing on integration activities. Supplies to start from Q2FY27.

❖ **Building Portfolio of Differentiated and Specialty Products**

- Continued investment in 505(b)(2), complex / differentiated generics, branded products, in-licensing and co-development to strengthen long-term growth.

Revenue Performance

(In ₹ Crore)



Note: Source for all market share data: IQVIA.

Consumer Healthcare Business: Sustaining Growth Momentum

Piramal Pharma Limited

Key Highlights

❖ **Delivered robust growth of 15% in Q1FY27 driven by:**

- **Power Brands - Delivered 23% YoY** growth, contributing 53% of PCH sales.
- **E-commerce - Delivered 40% YoY** growth, contributing 28% of PCH sales.

❖ **New Product Launches – Fewer – Bigger – Better**

- Focused on fewer, high-potential product launches with stronger success rates.
- **Premiumization of the portfolio with emphasis on higher-margin products.**

❖ **Continuous Investments in Media & Trade Promotion**

- Invested ~12% of PCH sales in media and trade **promotion across digital and traditional channels -** Social Media, Television, Influencers, etc.

❖ **Expand Multi-channel Distribution Network**

- Presence across **180,000+** chemists & cosmetic shops, **13,000+** modern trade outlets, and **20+** e-commerce platforms.
- Expanding reach in smaller towns, modern trade, and non-chemist channels.

❖ **Focused on Profitability Improvement Amid a Challenging Cost Environment**

- Judicious **price increase and cost optimization** initiatives offset raw material inflation.

Revenue Performance

(In ₹ Crore)



Focus on Power Brands with Brand Promotion and Marketing

(In ₹ Cr)



(In ₹ Cr)



AbbVie Therapeutics India Pvt. Ltd. - JV between AbbVie & PPL

Piramal Pharma Limited

FY2026 PERFORMANCE

₹526 Cr.
Revenue

23%
PAT Margin

Strong profitability and established market position

LEADING MARKET POSITION

One of the market leaders in the Indian ophthalmology segment

INTEGRATED SOLUTIONS

PPL CDMO business supplies ophthalmology products to the JV

Piramal Pharma Limited
Ownership **49%**

abbvie
Ownership **51%**

MARKET LEADING BRANDS	Pred Forte	Lumigan	Combigan	Refresh Tears	Alphagan
	Eye Inflammation	Glaucoma	Glaucoma	Dry Eyes	Glaucoma

Financials

Piramal
Pharma Limited

Consolidated Financials Highlights

Piramal Pharma Limited

Healthy Growth Across Businesses with EBITDA Margin Expansion

(in ₹ Cr. or as stated)

Particulars	Q1FY27	Q1FY26	% Change
Revenue from Operations[1]	**2,270**	**1,934**	**17%**
CDMO	1,187	997	19%
CHG	743	637	17%
PCH	347	302	15%
EBITDA	**285**	**165**	**72%**
EBITDA Margin	**12.5%**	**8.5%**	
PAT (before exceptional item)	**(69)**	**(102)**	**32%**
Exceptional Item	-	21	NM
PAT (after exceptional item)	**(69)**	**(82)**	**15%**

1. Revenue from Operations includes foreign exchange gains/losses

Dial-in Details for Q1FY27 Earnings Conference Call

Piramal Pharma Limited

Event	Location & Time	Telephone Number
Conference call on **30th July 2026**	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 12:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 05:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call –Click here	

For Investor Queries:

Gagan Borana
Investor Relations and Enterprise Risk Management
Email: gagan.borana@piramal.com

Madhusudan Dalmia
Investor Relations
Email: madhusudan.dalmia@piramal.com

Our Websites:-

Piramal Pharma Limited
www.piramalpharma.com

CDMO
www.piramalpharmasolutions.com

Complex Hospital Generics
www.piramalcriticalcare.com